EU approves TRYNGOLZA (olezarsen) for severe hypertriglyceridemia – Ionis
Ionis Pharmaceuticals, Inc. announced that the European Commission (EC) has approved TRYNGOLZA (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]).
TRYNGOLZA is the first and only RNA-targeted therapy authorized in the EU for adults with sHTG ≥880 mg/dL (≥10 mmol/L). The approval follows an early positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October and expands the marketing authorization for TRYNGOLZA, which is already indicated for familial chylomicronemia syndrome (FCS), into a broader patient population.
The EU approval is based on results from the pivotal Phase 3 CORE and CORE2 studies in adult patients with sHTG and triglyceride levels ≥880 mg/dL (≥10 mmol/L). These studies met their primary endpoint, with TRYNGOLZA demonstrating a statistically significant placebo-adjusted mean reduction in fasting triglyceride levels and reduction in acute pancreatitis events. TRYNGOLZA demonstrated a favorable safety and tolerability profile. The data were published in The New England Journal of Medicine.
“This approval is based on the robust clinical evidence supporting the compelling profile of TRYNGOLZA for sHTG and an example of the broad impact of Ionis’ science,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “We are proud to work with our long-standing partner Sobi to bring TRYNGOLZA to people in need across the EU.”
“Acute pancreatitis is a potentially life-threatening medical emergency that may require intensive care admission and prolonged hospitalization,” said Erik S.G. Stroes, MD, PhD, professor of vascular medicine, Amsterdam UMC. “Some patients experience permanent organ damage and lasting effects on their quality of life. There is an unmet need for patients with sHTG for new, effective therapies to help reduce the risk of acute pancreatitis.”
“The European Commission’s approval of TRYNGOLZA for the treatment of sHTG is an important step forward for patients in Europe who remain at increased risk of acute pancreatitis despite diet and existing lipid-lowering therapies,” said Lydia Abad-Franch, MD, head of R&D and medical affairs and chief medical officer, Sobi. “The EU decision marks meaningful progress for eligible patients living with sHTG.”
TRYNGOLZA was discovered, developed and is commercialized in the U.S. by Ionis Pharmaceuticals. The FDA approved TRYNGOLZA in June as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG (triglycerides ≥500 mg/dL). Sobi and Ionis entered into a license agreement under which Sobi has exclusive rights to commercialize TRYNGOLZA in ex-U.S. geographies except Canada and China.
About the CORE and CORE2 Studies
CORE (NCT05079919; n=617) and CORE2 (NCT05552326; n=446), conducted with The TIMI Study Group, are Phase 3 global, multicenter, randomized, double-blind, placebo-controlled trials investigating the safety and efficacy of olezarsen for severe hypertriglyceridemia (sHTG). Participants aged 18 and older with triglyceride levels ≥500 mg/dL (≥5.65 mmol/L) were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 43% of participants had fasting triglycerides ≥880 mg/dL (≥10 mmol/L). Participants were randomized to receive 50 mg or 80 mg of olezarsen or placebo every four weeks via subcutaneous injection for 12 months. The primary endpoint was the percentage change from baseline in fasting triglycerides at six months compared to placebo.
Citation: Marston NA, Bergmark BA et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394:429 DOI: 10.1056/NEJMoa25127




